BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27303300)

  • 1. PACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR Expression.
    Maugeri G; D'Amico AG; Reitano R; Magro G; Cavallaro S; Salomone S; D'Agata V
    Front Pharmacol; 2016; 7():139. PubMed ID: 27303300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory role of PACAP and VIP on HIFs expression in lung adenocarcinoma.
    D'Amico AG; Maugeri G; Rasà DM; Reitano R; Saccone S; Federico C; Magro G; D'Agata V
    Peptides; 2021 Dec; 146():170672. PubMed ID: 34627957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptides of the VIP family inhibit glioblastoma cell invasion.
    Cochaud S; Meunier AC; Monvoisin A; Bensalma S; Muller JM; Chadéneau C
    J Neurooncol; 2015 Mar; 122(1):63-73. PubMed ID: 25563813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PACAP and VIP regulate hypoxia-inducible factors in neuroblastoma cells exposed to hypoxia.
    Maugeri G; D'Amico AG; Rasà DM; Saccone S; Federico C; Cavallaro S; D'Agata V
    Neuropeptides; 2018 Jun; 69():84-91. PubMed ID: 29699729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PKA at a Cross-Road of Signaling Pathways Involved in the Regulation of Glioblastoma Migration and Invasion by the Neuropeptides VIP and PACAP.
    Bensalma S; Turpault S; Balandre AC; De Boisvilliers M; Gaillard A; Chadéneau C; Muller JM
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PACAP and VIP increase the expression of myelin-related proteins in rat schwannoma cells: involvement of PAC1/VPAC2 receptor-mediated activation of PI3K/Akt signaling pathways.
    Castorina A; Scuderi S; D'Amico AG; Drago F; D'Agata V
    Exp Cell Res; 2014 Mar; 322(1):108-21. PubMed ID: 24246222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PACAP and VIP Inhibit HIF-1α-Mediated VEGF Expression in a Model of Diabetic Macular Edema.
    Maugeri G; D'Amico AG; Saccone S; Federico C; Cavallaro S; D'Agata V
    J Cell Physiol; 2017 May; 232(5):1209-1215. PubMed ID: 27661459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
    Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
    Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
    Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
    Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
    Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.
    Wei Y; Mojsov S
    J Neuroendocrinol; 1996 Nov; 8(11):811-7. PubMed ID: 8933357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
    Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
    Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.